SLC17A6

Across TCGA pan-cancer cohorts, SLC17A6 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SLC17A6 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher SLC17A6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC17A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCS, SCLC, and LIHC are the cancer types where SLC17A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.104	0.688	<.001	36	view →
SCLC	OS	Median	All	0.261	0.520	.008	19	view →
LIHC	DFS	Median	All	0.186	0.548	.002	12	view →
CHOL	DFS	Median	All	0.037	0.486	.001	6	view →
UCEC	DFS	Median	All	0.926	0.611	.016	6	view →
GBM	OS	Median	All	0.116	0.419	.002	6	view →
LUAD	OS	Median	All	0.327	0.700	.034	6	view →
LUSC	OS	Median	All	0.765	0.387	.017	5	view →
READ	OS	Median	III,IV	0.328	0.751	.003	3	view →
HNSC	DFS	Median	II,III,IV	1.000	0.585	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SLC17A6–UCS (OS)

Open the UCS breakdown →